HLF · Herbalife Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.04B | $4.99B | $5.06B | $5.20B | $5.80B | $5.54B |
| Cost of Revenue | $1.11B | $1.10B | $1.19B | $1.17B | $1.24B | $1.15B |
| Gross Profit | $3.92B | $3.89B | $3.87B | $4.03B | $4.56B | $4.39B |
| R&D | - | - | - | - | - | - |
| SG&A | $1.73B | $1.88B | $1.87B | $1.81B | $2.01B | $2.08B |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $121.20M | $121.40M | $113.30M | $115.40M | $107.60M | $100.30M |
| Operating Income | $481.00M | $385.90M | $356.40M | $545.20M | $734.10M | $640.60M |
| Interest Expense | $214.40M | $218.30M | $165.90M | $139.30M | $153.10M | $133.00M |
| Income Tax | $47.30M | ($84.90M) | $60.80M | $103.50M | $113.60M | $143.80M |
| Net Income | $228.30M | $254.30M | $142.20M | $321.30M | $447.20M | $372.60M |
| EPS - Basic | $2.22 | $2.53 | $1.44 | $3.26 | $4.22 | $2.83 |
| EPS - Diluted | $2.20 | $2.50 | $1.42 | $3.23 | $4.13 | $2.77 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $353.10M | $415.30M | $575.20M | $508.00M | $601.50M | $1.05B |
| Accounts Receivable | $91.90M | $68.90M | $81.20M | $70.60M | $66.90M | $83.30M |
| Inventory | $511.70M | $475.40M | $505.20M | $580.70M | $575.70M | $501.40M |
| Accounts Payable | $99.80M | $70.00M | $84.00M | $89.80M | $92.00M | $88.70M |
| Current Assets | $1.14B | $1.14B | $1.40B | $1.36B | $1.43B | $1.78B |
| Total Assets | $2.79B | $2.73B | $2.81B | $2.73B | $2.82B | $3.08B |
| Current Liabilities | $1.01B | $1.23B | $1.28B | $976.60M | $1.08B | $1.13B |
| Long-term Debt | $1.97B | $1.98B | $2.25B | $2.66B | $2.73B | $2.41B |
| Total Liabilities | $3.30B | $3.53B | $3.87B | $4.00B | $4.21B | $3.93B |
| Stockholders' Equity | ($515.10M) | ($801.10M) | ($1.06B) | ($1.27B) | ($1.39B) | ($856.10M) |
| Retained Earnings | ($579.70M) | ($808.00M) | ($1.06B) | ($1.20B) | ($1.17B) | ($687.40M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $333.30M | $285.40M | $357.50M | $352.50M | $460.30M | $628.60M |
| Investing Cash Flow | ($108.70M) | ($84.60M) | ($134.80M) | ($156.20M) | ($156.40M) | ($123.20M) |
| Financing Cash Flow | ($295.50M) | ($335.30M) | ($148.30M) | ($264.70M) | ($728.60M) | ($320.90M) |
| CapEx | $80.40M | $122.00M | $135.00M | $156.40M | $151.40M | $112.00M |
| Free Cash Flow | $252.90M | $163.40M | $222.50M | $196.10M | $308.90M | $516.60M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 77.9% | 77.9% | 76.5% | 77.4% | 78.6% | 79.2% |
| Operating margin | 9.5% | 7.7% | 7.0% | 10.5% | 12.7% | 11.6% |
| EBITDA margin | 12.0% | 10.2% | 9.3% | 12.7% | 14.5% | 13.4% |
| Net margin | 4.5% | 5.1% | 2.8% | 6.2% | 7.7% | 6.7% |
| Free cash flow margin | 5.0% | 3.3% | 4.4% | 3.8% | 5.3% | 9.3% |
| FCF / Net income | 1.11 | 0.64 | 1.56 | 0.61 | 0.69 | 1.39 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 34.3% | 37.6% | 36.9% | 34.8% | 34.7% | 37.4% |
| Effective tax rate | 17.2% | -50.1% | 30.0% | 24.4% | 20.3% | 27.8% |
| Return on assets | 8.2% | 9.3% | 5.1% | 11.8% | 15.9% | 12.1% |
| Return on equity | -44.3% | -31.7% | -13.4% | -25.4% | -32.1% | -43.5% |
| Return on invested capital | 27.4% | 32.8% | 20.9% | 29.5% | 43.6% | 29.8% |
| Liquidity | ||||||
| Current ratio | 1.13 | 0.93 | 1.10 | 1.39 | 1.33 | 1.58 |
| Quick ratio | 0.62 | 0.54 | 0.70 | 0.79 | 0.79 | 1.13 |
| Cash ratio | 0.35 | 0.34 | 0.45 | 0.52 | 0.56 | 0.93 |
| Leverage | ||||||
| Debt / Equity | -3.83 | -2.47 | -2.12 | -2.10 | -1.96 | -2.81 |
| Debt / Assets | 0.71 | 0.72 | 0.80 | 0.97 | 0.97 | 0.78 |
| Debt / EBITDA | 3.27 | 3.90 | 4.80 | 4.03 | 3.25 | 3.25 |
| Interest coverage | 2.2x | 1.8x | 2.1x | 3.9x | 4.8x | 4.8x |
| Equity multiplier | -5.41 | -3.41 | -2.65 | -2.16 | -2.03 | -3.59 |
| Liabilities / Assets | 1.18 | 1.29 | 1.38 | 1.46 | 1.49 | 1.28 |
| Efficiency | ||||||
| Asset turnover | 1.81 | 1.83 | 1.80 | 1.90 | 2.06 | 1.80 |
| Inventory turnover | 2.18 | 2.32 | 2.36 | 2.02 | 2.15 | 2.29 |
| Days sales outstanding | 7d | 5d | 6d | 5d | 4d | 5d |
| Days inventory outstanding | 168d | 157d | 155d | 181d | 170d | 159d |
| Days payable outstanding | 33d | 23d | 26d | 28d | 27d | 28d |
| Cash conversion cycle | 142d | 139d | 135d | 158d | 147d | 136d |
| Valuation | ||||||
| P / E | 5.9x | 2.7x | 10.7x | 4.6x | 9.9x | 17.3x |
| P / B | - | - | - | - | - | - |
| P / S | 0.3x | 0.1x | 0.3x | 0.3x | 0.8x | 1.2x |
| EV / EBITDA | 4.9x | 4.4x | 6.8x | 5.5x | 7.8x | 10.6x |
| Growth | ||||||
| Revenue growth (YoY) | 0.9% | -1.4% | -2.7% | -10.3% | 4.7% | 13.6% |
| Revenue CAGR (3y) | -1.1% | -4.9% | -3.0% | 2.2% | 8.9% | 7.8% |
| Revenue CAGR (5y) | -1.9% | 0.5% | 2.4% | 3.3% | 5.3% | 4.4% |
| Gross profit growth (YoY) | 0.9% | 0.4% | -4.0% | -11.7% | 3.9% | 12.0% |
| Operating income growth (YoY) | 24.6% | 8.3% | -34.6% | -25.7% | 14.6% | 12.8% |
| Net income growth (YoY) | -10.2% | 78.8% | -55.7% | -28.2% | 20.0% | 19.8% |
| EPS growth (YoY) | -12.0% | 76.1% | -56.0% | -21.8% | 49.1% | 25.9% |
| EPS CAGR (3y) | -12.0% | -15.4% | -20.0% | 13.7% | 27.8% | 2.4% |
| EPS CAGR (5y) | -4.5% | 2.6% | -6.4% | 4.6% | 6.5% | -6.9% |
| FCF growth (YoY) | 54.8% | -26.6% | 13.5% | -36.5% | -40.2% | 47.0% |
| FCF CAGR (5y) | -13.3% | -14.2% | -4.7% | -16.9% | 6.6% | -1.2% |
| Book value growth (YoY) | 35.7% | 24.4% | 16.2% | 9.0% | -62.5% | -119.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$5.04B totalWeight Management$2.75B · 54.5%
Targeted Nutrition$1.51B · 30.0%
Energy Sports And Fitness$617.10M · 12.3%
Outer Nutrition$85.00M · 1.7%
Literature Promotional And Other$79.10M · 1.6%
Geographic
$9.80B totalPrimary Reporting Segment$4.76B · 48.6%
Others$2.03B · 20.7%
US$1.01B · 10.3%
IN$889.60M · 9.1%
MX$557.70M · 5.7%
CN$279.10M · 2.8%
VN$278.20M · 2.8%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
2.13
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing HERBALIFE LTD. against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Feb 28, 2014 | $0.1500 |
| Nov 7, 2013 | $0.1500 |
| Aug 9, 2013 | $0.1500 |
| May 10, 2013 | $0.1500 |
| Mar 1, 2013 | $0.1500 |
| Nov 9, 2012 | $0.1500 |
| Aug 10, 2012 | $0.1500 |
| May 11, 2012 | $0.1500 |
| Mar 5, 2012 | $0.1500 |
| Nov 9, 2011 | $0.1000 |
| Aug 11, 2011 | $0.1000 |
| May 20, 2011 | $0.0500 |
| Mar 4, 2011 | $0.0625 |
| Nov 10, 2010 | $0.0625 |
| Aug 10, 2010 | $0.0625 |
| May 6, 2010 | $0.0500 |
| Feb 26, 2010 | $0.0500 |
| Nov 23, 2009 | $0.0500 |
| Aug 26, 2009 | $0.0500 |
| May 20, 2009 | $0.0500 |
| Feb 27, 2009 | $0.0500 |
| Nov 21, 2008 | $0.0500 |
| Aug 25, 2008 | $0.0500 |
| May 28, 2008 | $0.0500 |